Theriva Biologics advances Phase 3 trial plans for cancer drug VCN-01 with FDA alignment and new data.

Theriva Biologics reported Q1 2026 results highlighting FDA alignment on the Phase 3 trial design for VCN-01, a cancer drug targeting metastatic pancreatic ductal adenocarcinoma (PDAC). New data from the Phase 2b VIRAGE trial suggest VCN-01 may work through an immune-mediated mechanism, improving survival and tumor response, especially with repeated dosing. The company plans a dosing feasibility study in Spain and is advancing a potential Phase 2/3 trial for retinoblastoma using VCN-01 with topotecan. Cash reserves stand at $14.4 million, supporting operations into Q1 2027.